Soon to be revealed: latest EMA thinking on trial data disclosure
This article was originally published in SRA
In just over two weeks' time we will have a better idea of how the European Medicines Agency plans to implement its decision on the proactive publication of clinical trial data on authorized drugs, when it releases the recommendations of the five advisory groups set up following last year's workshop on trial data and transparency1.
You may also be interested in...
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.